OUR PEOPLE

​Dr. Aiphi Nguyen, is co-founder and the CEO: Aiphi has more than 18 years experience in the pharmaceutical industry and the investment bank with a strong entrepreneurship orientation in goals and choice. Aiphi held various positions with Bristol Myers Squib (BMS) in regulatory, medico-marketing within the peadiatric field for which she gained tractions such as world successful launch of a specific range products intented to the treatment of inborn metabolic disorders, notified in the BMS 2003 annual report.
Then, Aiphi steered her carrier into the investment bank working with valuation team supporting various life sciences mandates. Aiphi has a twofold background in pharmacy and business, is a PharmD and hold an MBA from Sorbone University, a master in corporate finance from ESCP Europe and “Challenge plus” startup certification from HEC.

Dr Manel Kraiem Merabet is the Chief Development Officer. Manel has more than 9 years of experience in translational and clinical research in cancer centers, hospitals, biotech developing innovating therapies. Prior to Skymab, she served for 6 years as a senior project manager at Innate Pharma where she successfully led all aspects of science, CMC and strategy for multiple ADC projects from lead optimization through candidate selection until IND.
Regarded as an ADC expert, she has been part of discussion panel in World ADC congress in 2022, 2023 and 2024. Manel is a PharmD and hold a PhD in Oncology and immunology from CRCM, a DESC, European radiopharmacy-radiobiology degree from CEA Saclay and Master degree in organic chemistry from Saint Jerome university.

Caroline Mouline is the Director of Operations at Skymab, bringing over 10 years of expertise in biotherapies. She has worked in both academic settings (CNRS, GICC) and industry, notably as an R&D project manager at Kercell Biosciences, where she co-led an immunotherapy program focused on blood diseases. Caroline is a seasoned expert in immunotherapy and cell therapy, with deep knowledge in antibody engineering. She holds a PhD in molecular and cell biology from the University of Sofia Antipolis.

Jan Schellens, MD, PhD serves as the part-time Chief Medical Officer (CMO) at Skymab, contributing his vast expertise in oncology drug development to the company’s mission. With over 25 years of experience, Dr. Schellens has held key roles, including CMO at Byondis, where he advanced antibody-drug conjugates (ADCs) for cancer treatment, and at Modra Pharmaceuticals, where he worked on oral taxane therapies. He is also currently the CMO at Lixte Biotechnology Holdings, focused on innovative cancer therapies.

Dr. Schellens has been actively involved in regulatory affairs, serving over a decade on the Scientific Advisory Board for Oncology at the European Medicines Agency (EMA) and as a member of the Dutch Medicines Evaluation Board. He has authored more than 750 scientific publications, making significant contributions to oncology and pharmacology.